Article info
PDFResearch ethics
Gene therapy for children with cystic fibrosis—who has the right to choose?
- Correspondence to: Dr Adam Jaffé MD FRCPCH, FRCP Consultant and Honorary Senior Lecturer in Respiratory Research, Portex Respiratory Medicine Group, Level 6 Cardiac Wing, Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health, Great Ormond Street, London, WC1N 3JH, UK; a.jaffe{at}ich.ucl.ac.uk
Citation
Gene therapy for children with cystic fibrosis—who has the right to choose?
Publication history
- Received May 4, 2005
- Accepted August 30, 2005
- Revised June 26, 2005
- First published May 26, 2006.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by the Journal of Medical Ethics
Other content recommended for you
- Cystic fibrosis
- Gene therapy in cystic fibrosis
- Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation
- A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
- Recent developments and current status of gene therapy using viral vectors in the United Kingdom
- Science, medicine, and the future: Gene therapy
- Delivery of genes into the CF airway
- Gene therapy: targeting the myocardium
- Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
- Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis